L. Oste

发表

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis.

T. Christophe, C. Menet, B. Allart, 2021, Journal of medicinal chemistry.

A multiparameter approach to monitor disease activity in collagen-induced arthritis

G. Verbruggen, D. Elewaut, M. Drennan, 2010, Arthritis research & therapy.

Strontium incorporates at sites critical for bone mineralization in rats with renal failure

M. Drakopoulos, S. Bohic, S. Verberckmoes, 2007 .

Role of Dietary Phosphorus and Degree of Uremia in the Development of Renal Bone Disease in Rats

M. D. de Broe, L. Oste, V. Van Hoof, 2007, Renal failure.

Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats.

M. D. de Broe, S. Verberckmoes, L. Lamberts, 2005, Kidney international.

Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.

L. Nelles, S. Dupont, N. Triballeau, 2014, Journal of medicinal chemistry.

Discovery of 9-cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.

L. Nelles, G. Milligan, S. Dupont, 2020, Journal of medicinal chemistry.

Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.

M. D. de Broe, J. Denton, A. Cox, 2005, Kidney international.

Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.

R. Blust, M. D. de Broe, L. Oste, 2006, Bone.

Effects of Strontium on the Physicochemical Characteristics of Hydroxyapatite

M. Drakopoulos, P. Cool, A. Somogyi, 2004, Calcified Tissue International.

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib

N. Triballeau, M. Lamers, B. Hrvačić, 2017, Journal of medicinal chemistry.

IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases

S. Dupont, P. Fallon, K. Eyerich, 2023, Science Translational Medicine.

Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases.

N. Triballeau, Denis Bucher, T. Christophe, 2021, Journal of medicinal chemistry.

Resolving trabecular metaphyseal bone profiles downstream of the growth plate adds value to bone histomorphometry in mouse models

G. Kerckhofs, P. Salmon, B. Javaheri, 2023, Frontiers in Endocrinology.